SequelSEC

VACCINEX, INC. VCNX

Pharmaceutical Preparations · CIK 0001205922 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$601.00K
Fiscal year ended 2024-12-31
Operating income
-$18.74M
Fiscal year ended 2024-12-31
Free cash flow
-$16.21M
Fiscal year ended 2024-12-31

VACCINEX, INC. (VCNX) reported revenue of $601.00K and net income of -$18.63M for the fiscal year ended 2024-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from VACCINEX, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

VACCINEX, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$601.00K$570.00K$275.00K$900.00K$625.00K$523.00K$724.00K$90.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailable$2.00K$199.00K$1.03M$160.00K
Gross profitUnavailableUnavailableUnavailableUnavailable$623.00K$324.00K-$309.00K-$70.00K
Operating income-$18.74M-$22.88M-$19.91M-$22.49M-$28.33M-$32.02M-$27.28M-$21.10M
Net income-$18.63M-$20.25M-$19.82M-$22.38M-$28.85M-$31.86M-$29.52M-$18.72M
Research & development$12.54M$16.57M$13.98M$17.16M$21.55M$25.67M$22.35M$16.55M
Weighted-average diluted sharesshares 2.10MUnavailableUnavailableshares 28.85MUnavailableUnavailableUnavailableUnavailable
Pretax income-$18.63M-$20.25M-$19.82M-$22.38M-$28.85M-$31.86M-$29.52M-$18.76M
Income tax expense$0$0$0$0$0$0$0$0
Diluted EPS$-8.88$-43.68$-98.05$-0.78UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.79M$6.88M$6.20M$6.23M$7.40M$6.67M$4.62M$4.48M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

VACCINEX, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Cash & equivalents$1.11M$1.54M$6.39M$8.59M$10.60M$2.78M$5.62M$4.18M
Total assets$2.60M$3.63M$7.98M$9.84M$11.70M$4.60M$22.03M$5.58M
Current assets$2.53M$3.35M$7.48M$9.40M$11.29M$4.01M$21.42M$4.97M
Total liabilities$5.08M$5.94M$2.78M$2.43M$14.31M$6.88M$6.69M$7.35M
Current liabilities$5.08M$5.92M$2.54M$2.26M$13.18M$6.88M$6.69M$4.16M
Total equity incl. NCI-$2.49M-$2.31M$5.19M$7.41M-$2.61M-$2.27M$15.34M-$113.49M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$111.72M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$838.00K$961.00K$175.00KUnavailable$157.00K$898.00K$639.00K$117.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$0$26.00K$101.00K$175.00K$1.13MUnavailableUnavailableUnavailable
Accounts payable$3.96M$2.04M$1.52M$1.06M$3.17M$3.21M$2.32M$1.91M

Cash flow

VACCINEX, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Operating cash flow-$16.19M-$21.38M-$19.07M-$25.30M-$28.65M-$30.72M-$25.28M-$21.39M
Capital expenditures$22.00K$67.00K$99.00K$32.00K$290.00K$78.00K$235.00K$68.00K
Investing cash flow-$22.00K-$67.00K-$99.00K-$32.00K-$290.00K$14.07M-$14.24M-$68.00K
Financing cash flow$15.78M$16.59M$16.98M$23.32M$36.76M$13.80M$40.96M$23.97M
Net change in cash-$428.00K-$4.86M-$2.20M-$2.01M$7.82M-$2.84M$1.44M$2.52M
Stock-based compensation$341.00K$474.00K$545.00K$541.00K$732.00K$447.00K$177.00K$319.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable$249.00K$223.00K$206.00K

Derived

VACCINEX, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Free cash flow-$16.21M-$21.45M-$19.17M-$25.33M-$28.94M-$30.79M-$25.51M-$21.46M
Gross marginUnavailableUnavailableUnavailableUnavailable99.7%62.0%-42.7%-77.8%
Operating margin-3117.3%-4014.9%-7238.5%-2498.9%-4533.0%-6121.4%-3768.1%-23448.9%
FCF margin-2696.8%-3762.5%-6972.0%-2814.4%-4629.9%-5887.8%-3523.6%-23838.9%
SBC / revenue56.7%83.2%198.2%60.1%117.1%85.5%24.4%354.4%
Current ratio0.50x0.57x2.95x4.17x0.86x0.58xUnavailable1.19x
Revenue YoY growth5.4%107.3%-69.4%44.0%19.5%-27.8%704.4%Unavailable
Net margin-3100.5%-3552.8%-7205.5%Unavailable-4616.2%-6092.4%-4077.1%-20802.2%
R&D / revenue2087.4%2907.7%5083.3%1906.7%3447.8%4908.2%3087.4%18390.0%
CapEx / revenue3.7%11.8%36.0%3.6%46.4%14.9%32.5%75.6%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VCNX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2025-04-15View SEC filing
10-Q · Filed 2024-11-14View SEC filing
10-Q · Filed 2024-08-14View SEC filing
10-Q · Filed 2024-05-15View SEC filing
10-K/A · Filed 2024-04-25View SEC filing
10-K · Filed 2024-04-02View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.